Last Call for Comments on Bipartisan Discussion Draft SUSTAIN Act: Shaping 340B for the Future

Only a few days remain for stakeholders—which includes drug manufacturers, patients, health care providers, pharmacies and others— to take advantage of a rare opportunity to influence the statutory contours of the 340B Drug Pricing Program (the “340B Program” or the “Program”). Specifically, industry stakeholders have until April 1st to submit comments to legislators regarding the Discussion Draft Explanatory Statement and Supplemental RFI (the “RFI”) for the “Supporting Underserved and…
By: Epstein Becker & Green
Previous Story

USPTO Addresses Ambiguities in Means-Plus-Function, Step-Plus-Function Claims

Next Story

Antitrust & Competition Technology 2023 Year in Review